Lipskaia Larissa, Ly Hung, Kawase Yoshiaki, Hajjar Roger J, Lompre Anne-Marie
INSERM U621, Université Pierre et Marie Curie-CHU Pitié-Salpétriêre, Paris, France.
Future Cardiol. 2007 Jul;3(4):413-23. doi: 10.2217/14796678.3.4.413.
Heart failure is a major cause of morbidity and mortality in Western countries. While progress in conventional treatment modalities is making steady and incremental gains to reduce this disease burden, there remains a need to explore new and potentially therapeutic approaches. Gene therapy, for example, was initially envisioned as a treatment strategy for inherited monogenic disorders. It is now apparent that gene therapy has broader potential, which also includes acquired polygenic diseases such as heart failure. Advances in the understanding of the molecular basis of conditions such as these, together with the evolution of increasingly efficient gene transfer technology, has placed congestive heart failure within the reach of gene-based therapy.
心力衰竭是西方国家发病和死亡的主要原因。虽然传统治疗方式的进展正在稳步且逐步地减轻这种疾病负担，但仍有必要探索新的潜在治疗方法。例如，基因治疗最初被设想为一种治疗遗传性单基因疾病的策略。现在很明显，基因治疗具有更广泛的潜力，这也包括诸如心力衰竭等获得性多基因疾病。对这类疾病分子基础认识的进展，以及日益高效的基因转移技术的发展，使充血性心力衰竭有望通过基因治疗来攻克。
